<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Understanding Audra's Cancer: Interactive Dashboard</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            min-height: 100vh;
            padding: 20px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
        }

        .header {
            text-align: center;
            margin-bottom: 40px;
            color: #1a365d;
        }

        .header h1 {
            font-size: 2.5em;
            margin-bottom: 10px;
            font-weight: 700;
        }

        .header p {
            font-size: 1.1em;
            color: #2d3748;
            font-weight: 500;
        }

        .dashboard {
            display: grid;
            grid-template-columns: 1fr;
            gap: 20px;
            margin-bottom: 30px;
        }

        .widget {
            background: white;
            border-radius: 12px;
            box-shadow: 0 4px 6px rgba(0, 0, 0, 0.1);
            overflow: auto;
            transition: all 0.3s ease;
            cursor: pointer;
        }

        .widget:hover {
            box-shadow: 0 8px 12px rgba(0, 0, 0, 0.15);
            transform: translateY(-4px);
        }

        .widget-header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 20px;
            display: flex;
            justify-content: space-between;
            align-items: center;
            min-height: 70px;
        }

        .widget-header.bg-1 {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
        }

        .widget-header.bg-2 {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
        }

        .widget-header.bg-3 {
            background: linear-gradient(135deg, #4facfe 0%, #00f2fe 100%);
        }

        .widget-header.bg-4 {
            background: linear-gradient(135deg, #43e97b 0%, #38f9d7 100%);
        }

        .widget-header.bg-5 {
            background: linear-gradient(135deg, #fa709a 0%, #fee140 100%);
        }

        .widget-header.bg-6 {
            background: linear-gradient(135deg, #30cfd0 0%, #330867 100%);
        }

        .widget-header.bg-7 {
            background: linear-gradient(135deg, #a8edea 0%, #fed6e3 100%);
        }

        .widget-header.bg-8 {
            background: linear-gradient(135deg, #ff9a56 0%, #ff6a88 100%);
        }

        .widget-title {
            font-size: 1.3em;
            font-weight: 600;
            flex: 1;
        }

        .widget-icon {
            font-size: 1.8em;
            margin-left: 10px;
        }

        .widget-content {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.4s ease;
        }

        .widget.active .widget-content {
            max-height: 1000px;
        }

        .widget-body {
            padding: 20px;
            color: #2d3748;
            line-height: 1.8;
        }

        .widget-body h3 {
            color: #1a365d;
            margin-top: 15px;
            margin-bottom: 10px;
            font-size: 1.1em;
        }

        .widget-body h3:first-child {
            margin-top: 0;
        }

        .widget-body ul {
            margin-left: 20px;
            margin-bottom: 10px;
        }

        .widget-body li {
            margin-bottom: 8px;
        }

        .widget-body p {
            margin-bottom: 12px;
        }

        .key-stat {
            background: #f7fafc;
            border-left: 4px solid #667eea;
            padding: 12px 15px;
            margin: 12px 0;
            border-radius: 4px;
            font-weight: 500;
        }

        .key-stat.positive {
            border-left-color: #43e97b;
            background: #f0ffe9;
        }

        .key-stat.caution {
            border-left-color: #fa709a;
            background: #fff5f7;
        }

        .toggle-icon {
            display: inline-block;
            transition: transform 0.3s ease;
            font-size: 1.2em;
        }

        .widget.active .toggle-icon {
            transform: rotate(180deg);
        }

        .info-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 12px;
            margin: 15px 0;
        }

        .info-item {
            background: #f7fafc;
            padding: 12px;
            border-radius: 6px;
            border: 1px solid #e2e8f0;
        }

        .info-label {
            font-weight: 600;
            color: #667eea;
            font-size: 0.9em;
            text-transform: uppercase;
            margin-bottom: 5px;
        }

        .info-value {
            color: #1a365d;
            font-size: 1.1em;
            font-weight: 500;
        }

        .comparison-table {
            width: 100%;
            border-collapse: collapse;
            margin: 15px 0;
        }

        .comparison-table th {
            background: #edf2f7;
            padding: 10px;
            text-align: left;
            font-weight: 600;
            border-bottom: 2px solid #cbd5e0;
            color: #1a365d;
        }

        .comparison-table td {
            padding: 10px;
            border-bottom: 1px solid #e2e8f0;
        }

        .comparison-table tr:last-child td {
            border-bottom: none;
        }

        .footer {
            text-align: center;
            color: #4a5568;
            margin-top: 40px;
            padding: 20px;
            background: white;
            border-radius: 12px;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.05);
        }

        .footer p {
            margin: 8px 0;
            font-size: 0.95em;
        }

        @media (max-width: 768px) {
            .dashboard {
                grid-template-columns: 1fr;
            }

            .header h1 {
                font-size: 1.8em;
            }

            .info-grid {
                grid-template-columns: 1fr;
            }
        }

        .highlight {
            background: #fef5e7;
            padding: 2px 6px;
            border-radius: 3px;
            font-weight: 500;
            color: #d68910;
        }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>Understanding PPMS</h1>
            <p>A Personal Guide for Audra's Primary Pulmonary Myxoid Sarcoma</p>
        </div>

        <div class="dashboard">
            <!-- Widget 1: What is PPMS? -->
            <div class="widget">
                <div class="widget-header bg-1">
                    <span class="widget-title">What kind of tumor does Audra have, and how was it discovered?</span>
                    <span class="toggle-icon">▼</span>
                </div>
                <div class="widget-content">
                    <div class="widget-body">
                        <p>A 3-cm mass was discovered in Audra's lung, initially by X-ray, after an acute respiratory illness and persistent deep cough prompted a physician to order imaging.  Follow-up CT and PET scans confirmed the mass was still present weeks after the illness resolved (although the cough lingered), leading to a series of diagnostic procedures including a biopsy of the mass itself via an outpatient bronchoscopy.</p> 
                        
                        <p>Expert pathologists at UCSF re-evaluated the biopsy samples after initial panels were inconclusive, performing genetic tests in addition to looking for certain cancer-specific tumor features.  Genetic testing pointed to Primary Pulmonary Myxoid Sarcoma (PPMS), an <span class="highlight">exceptionally rare</span>, low-grade tumor that develops in the lungs. Audra's tumor has the rare genetic EWSR1 rearrangement that is "pathognomonic" for PPMS (that is, it essentially rules out other cancer types with high certainty).</p>

                        <h3>Key Characteristics of PPMS</h3>
                        <ul>
                            <li><strong>Rarity:</strong> Only ~39 cases documented worldwide</li>
                            <li><strong>Grade:</strong> Low-grade (slow-growing)</li>
                            <li><strong>Location:</strong> Typically in lung airways or tissue</li>
                            <li><strong>Origin:</strong> Arises from lung mesenchymal cells</li>
                        </ul>

                        <h3>Why the "Low-Grade" label Matters</h3>
                        <p>Low-grade means the tumor cells divide slowly and behave less aggressively than high-grade cancers. This translates directly to <strong>better outcomes</strong> and <strong>more treatment options</strong>.</p>

                        <div class="key-stat positive">
                            ✓ Low-grade status = slower growth = better prognosis
                        </div>

                        <h3>What makes it "myxoid"?</h3>
                        <p>Under the microscope, PPMS has a distinctive "jelly-like" (myxoid) appearance with delicate lace-like strands of spindle-shaped cells embedded in a gelatinous matrix. This unique pattern helps pathologists identify the tumor type, and significantly narrowed the list of possibilities in Audra's case.</p>
                    </div>
                </div>
            </div>

            <!-- Widget 2: Where Does PPMS Come From? -->
            <div class="widget">
                <div class="widget-header bg-2">
                    <span class="widget-title">Where do PPMS tumors come from?</span>
                    <span class="toggle-icon">▼</span>
                </div>
                <div class="widget-content">
                    <div class="widget-body">
                        <h3>Risk Factors & Causes</h3>
                        <p>PPMS does <strong>NOT</strong> result from smoking, environmental exposure, or anything Audra did or didn't do. It's a <span class="highlight">random genetic event</span>, probably occurring in adulthood (i.e. not inherited), and could happen to anyone.</p>

                        <div class="key-stat caution">
                            ⚠ PPMS is not linked to smoking, age, gender, or lifestyle factors
                        </div>

                        <h3>Who Gets PPMS?</h3>
                        <div class="info-grid">
                            <div class="info-item">
                                <div class="info-label">Age</div>
                                <div class="info-value">~44 years (average)</div>
                            </div>
                            <div class="info-item">
                                <div class="info-label">Gender</div>
                                <div class="info-value">Equal (M:F ≈ 1:1)</div>
                            </div>
                            <div class="info-item">
                                <div class="info-label">Smoking</div>
                                <div class="info-value">No correlation; Smokers and Non-smokers equally affected</div>
                            </div>
                            <div class="info-item">
                                <div class="info-label">Geographic</div>
                                <div class="info-value">No correlation with geography</div>
                            </div>
                        </div>

                        <h3>Where did it come from?</h3>
                        <p>PPMS arises from mesenchymal cells (structural cells) in the lung. A single cell experiences a chromosomal translocation—essentially a "typo" where parts of two chromosomes swap places—creating the EWSR1::CREB1 fusion gene.</p>

                        <p>This is a <strong>somatic mutation</strong>, meaning it happens <strong>only in that cell</strong>, not in Audra's entire body or inherited genes. It's not genetic in the hereditary sense—no family members are at increased risk.</p>
                    </div>
                </div>
            </div>

            <!-- Widget 3: Prognosis -->
            <div class="widget">
                <div class="widget-header bg-7">
                    <span class="widget-title">What is her prognosis based on what we know do far?</span>
                    <span class="toggle-icon">▼</span>
                </div>
                <div class="widget-content">
                    <div class="widget-body">
                        <h3>The Big Picture</h3>
                        <p>The prognosis for PPMS with EWSR1::CREB1 fusion is <span class="highlight">excellent</span>, especially when surgically resected with clean margins.</p>

                        <h3>What the Data Shows</h3>
                        <div class="key-stat positive">
                            ✓ <strong>85%</strong> of surgery patients had NO EVIDENCE OF DISEASE at final follow-up
                        </div>
                        <div class="key-stat positive">
                            ✓ Average follow-up without recurrence: <strong>3.5 years</strong> (range: 0.1–15 years)
                        </div>
                        <div class="key-stat caution">
                            ⚠ Metastasis rate: <strong>15%</strong> (5 out of 34 surgical patients)
                        </div>

                        <h3>Specific Favorable Factors</h3>
                        <p>Several aspects of Audra's case predict <strong>excellent outcomes</strong>:</p>
                        <table class="comparison-table">
                            <tr>
                                <th>Factor</th>
                                <th>Her Status</th>
                                <th>Impact</th>
                            </tr>
                            <tr>
                                <td><strong>Fusion type</strong></td>
                                <td>EWSR1::CREB1 (confirmed)</td>
                                <td>✓ Associated with better outcomes</td>
                            </tr>
                            <tr>
                                <td><strong>Tumor size</strong></td>
                                <td>3 cm (small)</td>
                                <td>✓ Smaller = lower risk</td>
                            </tr>
                            <tr>
                                <td><strong>Resectability</strong></td>
                                <td>Completely resectable</td>
                                <td>✓ Complete removal = best outcomes</td>
                            </tr>
                            <tr>
                                <td><strong>Age</strong></td>
                                <td>44 (young and healthy)</td>
                                <td>✓ Better physiological reserve</td>
                            </tr>
                            <tr>
                                <td><strong>Gender</strong></td>
                                <td>Female</td>
                                <td>✓ Slightly better outcomes than males</td>
                            </tr>
                            <tr>
                                <td><strong>Metastasis</strong></td>
                                <td>None at diagnosis</td>
                                <td>✓ localized disease = better prognosis</td>
                            </tr>
                            <tr>
                                <td><strong>Health Status</strong></td>
                                <td>Healthy, non-smoker</td>
                                <td>✓ Audra should better tolerate surgery/recovery</td>
                            </tr>
                        </table>

                        <h3>What About Those Who Had Metastasis?</h3>
                        <p>Of the 5 patients who developed metastasis:</p>
                        <ul>
                            <li>Sites included: pleura (lining), lung, bone, kidney, brain (1 case)</li>
                            <li>Most occurred months to years after surgery</li>
                            <li>One resulted in death (brain metastasis)</li>
                        </ul>
                        <p><strong>Important:</strong> Metastasis risk factors are not yet fully defined in PPMS. The presence of EWSR1 fusion alone does not predict who will have recurrence.</p>

                        <h3>Post-Surgery Surveillance</h3>
                        <p>Even with excellent prognosis, routine follow-up is important:</p>
                        <ul>
                            <li>Regular imaging (chest X-rays and CT scans)</li>
                            <li>Typically: scans every 6 months for 2 years, then annually</li>
                            <li>Early detection of any recurrence allows prompt intervention</li>
                        </ul>

                        <div class="key-stat positive">
                            ✓ Early detection of recurrence, when it occurs, enables intervention
                        </div>
                    </div>
                </div>
            </div>

            <!-- Widget 4: The Surgery -->
            <div class="widget">
                <div class="widget-header bg-5">
                    <span class="widget-title">What will the surgery be like?</span>
                    <span class="toggle-icon">▼</span>
                </div>
                <div class="widget-content">
                    <div class="widget-body">
                        <p>Fortunately, Audra's tumor can be removed through minimally-invasive, <strong>video-assisted thoracoscopic surgery</strong></p>

                        <h3>VATS: What It Means</h3>
                        <p><strong>VATS = Video-Assisted Thoracoscopic Surgery</strong></p>
                        <p>Instead of a large chest incision, the surgeon will make 2-4 small incisions between the ribs (about 1-2 cm each) and use a camera (thoracoscope) to guide the operation. Tools are inserted through these small ports.</p>

                        <div class="key-stat positive">
                            ✓ Minimally invasive = less pain, faster recovery, smaller scars
                        </div>

                        <h3>The Procedure Step-by-Step</h3>
                        <ol style="margin-left: 20px; margin-bottom: 15px;">
                            <li><strong>Positioning:</strong> Right side-lying (right lateral decubitus) to access left chest</li>
                            <li><strong>One-lung ventilation:</strong> Left lung is deflated so surgeon can work</li>
                            <li><strong>Vessel dissection:</strong> Pulmonary artery and vein to lower lobe are carefully identified and divided</li>
                            <li><strong>Bronchus division:</strong> The lower lobe airway is stapled</li>
                            <li><strong>Lobe removal:</strong> Entire left lower lobe containing tumor is removed</li>
                            <li><strong>Lymph node dissection:</strong> Regional lymph nodes examined and removed for staging</li>
                            <li><strong>Inspection:</strong> Remaining lung checked for air leaks and bleeding</li>
                            <li><strong>Closure:</strong> Chest tube placed; small incisions closed with sutures</li>
                        </ol>

                        <h3>Duration & Hospital Stay</h3>
                        <div class="info-grid">
                            <div class="info-item">
                                <div class="info-label">Surgery Time</div>
                                <div class="info-value">2-3 hours</div>
                            </div>
                            <div class="info-item">
                                <div class="info-label">Hospital Stay</div>
                                <div class="info-value">3-5 days</div>
                            </div>
                            <div class="info-item">
                                <div class="info-label">Chest Tube</div>
                                <div class="info-value">Usually 2-3 days</div>
                            </div>
                            <div class="info-item">
                                <div class="info-label">Return Home</div>
                                <div class="info-value">Day 3-5</div>
                            </div>
                        </div>

                        <h3>Why VATS vs. Open Surgery?</h3>
                        <table class="comparison-table">
                            <tr>
                                <th>Aspect</th>
                                <th>VATS</th>
                                <th>Open</th>
                            </tr>
                            <tr>
                                <td><strong>Incisions</strong></td>
                                <td>2-4 small (1-2 cm)</td>
                                <td>1 large (10+ cm)</td>
                            </tr>
                            <tr>
                                <td><strong>Pain</strong></td>
                                <td>Mild-moderate</td>
                                <td>Significant</td>
                            </tr>
                            <tr>
                                <td><strong>Recovery</strong></td>
                                <td>4-6 weeks</td>
                                <td>6-8 weeks</td>
                            </tr>
                            <tr>
                                <td><strong>Infection risk</strong></td>
                                <td>Lower</td>
                                <td>Higher</td>
                            </tr>
                            <tr>
                                <td><strong>Scars</strong></td>
                                <td>Minimal</td>
                                <td>Prominent</td>
                            </tr>
                        </table>

                        <p style="margin-top: 15px;"><strong>Bottom line:</strong> VATS is the modern standard for lung resection and offers significantly faster recovery with equivalent cancer control.</p>
                    </div>
                </div>
            </div>

            <!-- Widget 5: Recovery Timeline -->
            <div class="widget">
                <div class="widget-header bg-6">
                    <span class="widget-title">What will her recovery be like?</span>
                    <span class="toggle-icon">▼</span>
                </div>
                <div class="widget-content">
                    <div class="widget-body">
                        <h3>Days 1-3 (Hospital)</h3>
                        <ul>
                            <li>Chest tube in place (monitors fluid, prevents air accumulation)</li>
                            <li>Pain controlled with IV and oral medications</li>
                            <li>Breathing exercises and walking encouraged</li>
                            <li>Most patients feel tired and sore</li>
                            <li>Chest tube typically removed by day 2-3</li>
                        </ul>

                        <h3>Days 4-7 (Home Recovery Week 1)</h3>
                        <ul>
                            <li>Mild chest wall soreness (improves rapidly)</li>
                            <li>Fatigue is common—rest is important</li>
                            <li>Light activity: short walks around the house</li>
                            <li>No heavy lifting or strenuous activity</li>
                            <li>Pain management with oral medications</li>
                        </ul>

                        <h3>Week 2-3</h3>
                        <ul>
                            <li>Soreness continues to improve</li>
                            <li>Cough resolves as airway opens</li>
                            <li>Energy starts improving</li>
                            <li>Can return to self-care activities</li>
                            <li>Follow-up appointment with surgeon</li>
                        </ul>

                        <h3>Week 4-6</h3>
                        <ul>
                            <li>Most incisional pain resolves</li>
                            <li>Light work activities become possible</li>
                            <li>Can resume normal household activities</li>
                            <li>Gradually increasing walking/light exercise</li>
                        </ul>

                        <h3>Month 2-3</h3>
                        <ul>
                            <li>Return to work for most (desk work earlier than physical)</li>
                            <li>Shoulder stiffness may persist—gentle stretching helps</li>
                            <li>Most daily activities pain-free</li>
                            <li>Return to driving when comfortable and off narcotic pain meds</li>
                        </ul>

                        <h3>Month 3-6</h3>
                        <ul>
                            <li>Full recovery for most activities</li>
                            <li>Can return to pre-surgery fitness level</li>
                            <li>Remaining lung expands to compensate</li>
                            <li>Most emotional adjustment complete</li>
                        </ul>

                        <div class="key-stat positive">
                            ✓ Lower lobe resection patients may take a few extra days compared to upper lobe, but pulmonary function recovers completely within 6 months
                        </div>
                    </div>
                </div>
            </div>

            <!-- Widget 6: What About Chemotherapy & Radiation? -->
            <div class="widget">
                <div class="widget-header bg-4">
                    <span class="widget-title">Will she need chemo, radiation therapy, or immunotherapy?</span>
                    <span class="toggle-icon">▼</span>
                </div>
                <div class="widget-content">
                    <div class="widget-body">
                        <h3>The Short Answer</h3>
                        <p><strong>Surgery is the primary treatment for PPMS.</strong> Current evidence does <span class="highlight">NOT</span> support routine chemotherapy or radiation for PPMS after complete surgical resection.</p>

                        <div class="key-stat positive">
                            ✓ Audra most likely will NOT need chemotherapy or radiation
                        </div>

                        <h3>Why Surgery Alone?</h3>
                        <ul>
                            <li><strong>Complete resection is curative:</strong> When the entire tumor is removed with clean margins (R0 resection), outcomes are excellent</li>
                            <li><strong>Low-grade biology:</strong> Slow-growing tumors respond best to surgery; chemotherapy is less effective for low-grade disease</li>
                            <li><strong>Evidence-based:</strong> All documented cases with good outcomes had surgery as the primary treatment</li>
                            <li><strong>Safety:</strong> Avoiding unnecessary chemotherapy avoids side effects while maintaining cure rates</li>
                        </ul>

                        <h3>When Might Chemo Be Considered?</h3>
                        <p>Chemotherapy might be considered if:</p>
                        <ul>
                            <li>The tumor cannot be completely removed (R1/R2 resection)</li>
                            <li>The patient has metastatic (spread) disease at presentation</li>
                            <li>The tumor shows unusual aggressive features on pathology</li>
                        </ul>
                        <p><strong>None of these apply to Audra's case.</strong> Her tumor is localized, completely resectable, and shows typical low-grade features.</p>

                        <h3>The Upshot</h3>
                        <p>This is excellent news: months of chemotherapy aren't necessary, and Audra gets to focus on surgical recovery and a return to normal life.</p>
                    </div>
                </div>
            </div>

            <!-- Widget 7: Will It Come Back? -->
            <div class="widget">
                <div class="widget-header bg-8">
                    <span class="widget-title">Is there a chance the cancer could come back?</span>
                    <span class="toggle-icon">▼</span>
                </div>
                <div class="widget-content">
                    <div class="widget-body">
                        <h3>The Risk is Low</h3>
                        <p>Based on documented cases, <strong>~85% of surgery patients have no recurrence</strong>. For Audra, this means the probability favors long-term disease-free survival.</p>

                        <h3>Important Distinctions</h3>
                        <p><strong>Local recurrence</strong> (tumor growing back in the chest): <span class="highlight">Extremely rare</span> after VATS lobectomy, because the entire lobe containing the tumor is removed.</p>
                        <p><strong>Distant metastasis</strong> (spread to other organs): Possible, but fairly uncommon.</p>

                        <h3>Risk Factors for Metastasis (Unclear)</h3>
                        <p>Unlike some other cancers, PPMS prognostic factors are not yet fully understood. Current evidence suggests:</p>
                        <ul>
                            <li>Tumor size may matter (smaller = lower risk)</li>
                            <li>Complete resection improves outcomes</li>
                            <li>EWSR1::CREB1 fusion presence <strong>alone</strong> does not predict recurrence</li>
                            <li>High proliferation rate (many mitoses) <span class="highlight">might</span> suggest higher risk, but this is rare in PPMS</li>
                        </ul>

                        <h3>What to Do to Minimize Risk</h3>
                        <ul>
                            <li><strong>Attend follow-up appointments:</strong> Regular imaging detects recurrence early</li>
                            <li><strong>Report new symptoms:</strong> Unexplained cough, chest pain, shortness of breath warrant imaging</li>
                            <li><strong>Maintain health:</strong> Exercise, healthy diet, avoid smoking (she's ahead here!)</li>
                            <li><strong>Manage stress:</strong> Emotional wellness is part of recovery</li>
                        </ul>

                        <h3>The Reassuring Truth</h3>
                        <p><strong>85% of PPMS survivors achieve long-term disease-free status</strong>. Audra has many favorable factors pointing toward this disease-free 85% group. And, even if metastasis occurred, early detection through surveillance allows intervention.</p>

                        <div class="key-stat positive">
                            ✓ Probability favors very low chances of recurrence given Audra's profile
                        </div>

                        <div class="key-stat positive">
                            ✓ Surveillance allows early detection and intervention if needed
                        </div>
                    </div>
                </div>
            </div>

            <!-- Widget 8: The EWSR1::CREB1 Genetic Rearrangement -->
            <div class="widget">
                <div class="widget-header bg-3">
                    <span class="widget-title">For the nerds: How does the EWSR1::CREB1 genetic rearrangement lead to PPMS?</span>
                    <span class="toggle-icon">▼</span>
                </div>
                <div class="widget-content">
                    <div class="widget-body">
                        <h3>The Chromosomal Swap</h3>
                        <p>Normally, each cell has two copies of chromosome 2 and two copies of chromosome 22. In PPMS, a piece of chromosome 2 swaps with a piece of chromosome 22 at specific locations: <span class="highlight">t(2;22)(q33;q12)</span>.</p>

                        <p>This swap fuses the EWSR1 gene (from chr22) with the CREB1 gene (from chr2), creating a hybrid gene.</p>

                        <h3>What's the Problem with This Fusion?</h3>
                        <p>The fusion protein found in Audra's tumor is a "super-charged" version of the normal CREB1 protein:</p>
                        <ul>
                            <li><strong>EWSR1 portion:</strong> A powerful "transactivator" domain that cranks up gene activity</li>
                            <li><strong>CREB1 portion:</strong> A DNA-binding domain that targets specific genes</li>
                            <li><strong>Result:</strong> The fusion protein acts like a gas pedal stuck down on a specific set of genes</li>
                        </ul>

                        <h3>The Downstream Effects</h3>
                        <p>This fusion protein drives abnormal expression of target genes that promote:</p>
                        <ul>
                            <li>Cell proliferation (though slowly, due to low-grade biology)</li>
                            <li>Altered differentiation pathways</li>
                            <li>Changes in cell-cell adhesion</li>
                            <li>Myxoid matrix production (the "jelly-like" appearance)</li>
                        </ul>

                        <div class="key-stat positive">
                            ✓ Despite driving the tumor, EWSR1::CREB1 actually promotes <strong>slower</strong> growth than other fusion proteins
                        </div>

                        <h3>Why Low-Grade Despite the Fusion?</h3>
                        <p>Compared to other EWSR1 fusions (like EWSR1::FLI1 in Ewing sarcoma), the EWSR1::CREB1 fusion appears inherently less aggressive. This is why PPMS is reliably low-grade and why surgery is so effective.</p>
                    </div>
                </div>
            </div>
        </div>

        <div class="footer">
            <p><strong>Important Note:</strong> This dashboard is for educational purposes only.</p>
            <p>Information presented is based on peer-reviewed literature and clinical case series of PPMS.</p>
        </div>
    </div>

    <script>
        document.querySelectorAll('.widget').forEach(widget => {
            const header = widget.querySelector('.widget-header');
            header.addEventListener('click', () => {
                widget.classList.toggle('active');
            });
        });
    </script>
</body>
</html>

